Stocks
Neurocrine Biosciences Financial Statements (NBIX) |
||||||||||
| Neurocrine Biosciencessmart-lab.ru | % | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.10.2023 | 09.02.2024 | 01.05.2024 | 01.08.2024 | 30.10.2024 | 30.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 498.8 | 515.2 | 515.3 | 590.2 | 622.1 | 2 243 | |||
| Operating Income, bln rub | 141.2 | 150.3 | 105.3 | 147.9 | 183.8 | 587.3 | ||||
| EBITDA, bln rub | ? | 146.7 | 156.0 | 111.5 | 155.2 | 196.8 | 619.5 | |||
| Net profit, bln rub | ? | 83.1 | 147.7 | 43.4 | 65.0 | 129.8 | 385.9 | |||
| OCF, bln rub | ? | 212.0 | 123.5 | 130.3 | 64.6 | 158.0 | 476.4 | |||
| CAPEX, bln rub | ? | 7.60 | 5.40 | 11.2 | 11.6 | 8.10 | 36.3 | |||
| FCF, bln rub | ? | 204.4 | 118.1 | 119.1 | 53.0 | 149.9 | 440.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 346.4 | 356.4 | 397.2 | 426.7 | 430.3 | 1 611 | ||||
| Cost of production, bln rub | 11.2 | 8.50 | 12.8 | 15.6 | 8.00 | 44.9 | ||||
| R&D, bln rub | 142.2 | 137.5 | 154.1 | 184.7 | 195.0 | 671.3 | ||||
| Interest expenses, bln rub | 1.10 | 1.10 | 1.10 | 0.000 | 0.000 | 2.20 | ||||
| Assets, bln rub | 2 848 | 3 251 | 3 472 | 3 305 | 3 535 | 3 535 | ||||
| Net Assets, bln rub | ? | 2 002 | 2 232 | 2 386 | 2 509 | 2 719 | 2 719 | |||
| Debt, bln rub | 255.8 | 428.4 | 546.9 | 291.6 | 251.4 | 251.4 | ||||
| Cash, bln rub | 1 095 | 1 032 | 1 211 | 1 039 | 1 228 | 1 228 | ||||
| Net debt, bln rub | -839.3 | -603.2 | -663.7 | -747.3 | -976.6 | -976.6 | ||||
| Ordinary share price, rub | 112.5 | 131.8 | 137.9 | 137.7 | 115.2 | 113.4 | ||||
| Number of ordinary shares, mln | 97.9 | 98.4 | 99.8 | 100.8 | 101.1 | 101.1 | ||||
| Market cap, bln rub | 11 014 | 12 965 | 13 764 | 13 877 | 11 649 | 11 467 | ||||
| EV, bln rub | ? | 10 174 | 12 362 | 13 101 | 13 130 | 10 672 | 10 490 | |||
| Book value, bln rub | 1 967 | 2 191 | 2 352 | 2 470 | 2 684 | 2 684 | ||||
| EPS, rub | ? | 0.85 | 1.50 | 0.43 | 0.64 | 1.28 | 3.82 | |||
| FCF/share, rub | 2.09 | 1.20 | 1.19 | 0.53 | 1.48 | 4.35 | ||||
| BV/share, rub | 20.1 | 22.3 | 23.6 | 24.5 | 26.6 | 26.6 | ||||
| EBITDA margin, % | ? | 29.4% | 30.3% | 21.6% | 26.3% | 31.6% | 27.6% | |||
| Net margin, % | ? | 16.7% | 28.7% | 8.42% | 11.0% | 20.9% | 17.2% | |||
| FCF yield, % | ? | 3.49% | 2.79% | 4.46% | 3.56% | 3.78% | 3.84% | |||
| ROE, % | ? | 9.54% | 11.2% | 15.5% | 13.5% | 14.2% | 14.2% | |||
| ROA, % | ? | 6.71% | 7.68% | 10.6% | 10.3% | 10.9% | 10.9% | |||
| P/E | ? | 57.7 | 51.9 | 37.2 | 40.9 | 30.2 | 29.7 | |||
| P/FCF | 28.6 | 35.9 | 22.4 | 28.1 | 26.5 | 26.1 | ||||
| P/S | ? | 6.17 | 6.87 | 6.94 | 6.55 | 5.19 | 5.11 | |||
| P/BV | ? | 5.60 | 5.92 | 5.85 | 5.62 | 4.34 | 4.27 | |||
| EV/EBITDA | ? | 28.8 | 30.4 | 26.9 | 23.1 | 17.2 | 16.9 | |||
| Debt/EBITDA | -2.37 | -1.49 | -1.36 | -1.31 | -1.58 | -1.58 | ||||
| R&D/CAPEX, % | 1 871% | 2 546% | 1 376% | 1 592% | 2 407% | 1 849% | ||||
| CAPEX/Revenue, % | 1.52% | 1.05% | 2.17% | 1.97% | 1.30% | 1.62% | ||||
| Neurocrine Biosciences shareholders | ||||||||||
